Somatostatin Receptor Imaging in NPC, EBV Related Cancers

NCT05581550 | Completed

• 1 other identifier: NPC EBV SSTR
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

The study aims to describe the avidity of somatostatin receptors in locally advanced, metastatic and locally recurrent nasopharyngeal cancer (NPC) and to determine the proportion of NPC patients with high somatostatin receptor density that may benefit from future somatostatin targeted therapeutic trial plans. The investigators also aim to determine the presence of somatostatin receptors in other EBV related cancers.

Conditions

Nasopharyngeal Cancer; Epstein-Barr Virus Related Carcinoma

Keywords

Somatostatin; EBV; NPC; Rare Cancer

Outcome Measures

Primary Outcomes (1)

• Amount of tracer uptake in the tumour lesions of NPC patients

  The maximum standardized uptake values (SUVmax) will be measured. If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.

  From time of tracer injection to time the scan is performed

Secondary Outcomes (3)

• Amount of tracer uptake in the tumour lesions of patients with EBV related cancers

  From time of tracer injection to time the scan is performed

• Number of somatostatin receptors in patient biopsy samples

  Upon signing the informed consent form

• Amount of somatostatin circulating tumour cells in patient blood samples

  At the time of scan

Study Arms (1)

PET imaging

OTHER

Radiation: FDG-PET; Radiation: Galium-68 DOTATATE

Interventions

FDG-PET RADIATION

Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose. Scanning will be performed at an interval of at least 60 minutes following the injection.

PET imaging

Galium-68 DOTATATE RADIATION

200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.

PET imaging

Eligibility Criteria

• Age: 21 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
• Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
• Histologically confirmed NPC
• Above 21 years of age

You may not qualify if:

• Patients below 21 years of age
• Pregnant and breast feeding ladies

Sponsors & Collaborators

• National Cancer Centre, Singapore: lead
• National Cancer Centre Research Fund: collaborator

Study Sites (1)

National Cancer Centre Singapore

Singapore, Singapore

Location

MeSH Terms

Conditions

Nasopharyngeal Neoplasms

Condition Hierarchy (Ancestors)

Pharyngeal Neoplasms; Otorhinolaryngologic Neoplasms; Head and Neck Neoplasms; Neoplasms by Site; Neoplasms; Nasopharyngeal Diseases; Pharyngeal Diseases; Stomatognathic Diseases; Otorhinolaryngologic Diseases

Study Officials

• Wen Long Nei, MD

  National Cancer Centre, Singapore

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 9, 2021
• First Posted: October 14, 2022
• Study Start: June 29, 2020
• Primary Completion: July 17, 2025
• Study Completion: July 17, 2025
• Last Updated: July 20, 2025

Record last verified: 2025-07

Locations

SG (1)